Research ArticleResearch Article

The Relationship of EGFR and VEGF mRNA Expression in Ovarian Carcinoma

Aiping Chen, Ruirui Yang, Hongling Zhang and Hui Song
Clinical Oncology and Cancer Research April 2009, 6 (2) 100-103; DOI: https://doi.org/10.1007/s11805-009-0100-4

Article Figures & Data

Figures

  • The expression of EGFR mRNA and VEGF mRNA in ovarian carcinoma. M, DNA Maeker; 1-5, The expression of GAPDH mRNA in ovarian carcinoma; 6-7, The expression of EGFR mRNA or VEGF mRNA in ovarian carcinoma; 8-9, The expression of EGFR mRNA or VEGF mRNA in benign ovarian tumor; 10, The expression of EGFR mRNA or VEGF mRNA in normal ovary; 11, Negative control.
    Fig. 1.

    The expression of EGFR mRNA and VEGF mRNA in ovarian carcinoma. M, DNA Maeker; 1-5, The expression of GAPDH mRNA in ovarian carcinoma; 6-7, The expression of EGFR mRNA or VEGF mRNA in ovarian carcinoma; 8-9, The expression of EGFR mRNA or VEGF mRNA in benign ovarian tumor; 10, The expression of EGFR mRNA or VEGF mRNA in normal ovary; 11, Negative control.

Tables

  • Table 1.

    The expression of EGFR and VEGF gene in normal ovaries, benign ovarian tumors and ovarian cancer

    TypenEGFR+VEGF+
    n%χ2Pn%χ2P
    Normal ovaries15320.0*12.2710.000320.0*44.6340.000
    Benign tumors13430.8*5.4120.020538.5*30.4620.000
    Ovarian cancer513670.651100

    • ↵* P < 0.05 vs. ovarian cancer.

  • Table 2.

    Relationship between the EGFR mRNA expression and clinicopathologic features in ovarian cancer

    EGFR (+)EGFR expression
    Characteristicsn (%)Px ± sP
    Age, years
        ≥ 5117/24 (70.8)0.9710.99 ± 0.240.123
        < 5119/27 (70.4)0.83 ± 0.31
    Histological type
        Serous carcinoma27/39 (69.2)0.9830.90 ± 0.320.885
        Others9/12 (75.0)0.92 ± 0.18
    Differentiation
        Moderately/Well differentiated7/11 (63.6)0.5870.86 ± 0.180.577
        Poor differentiated31/40 (77.5)0.93 ± 0.33
    Clinical stage
        I-II8/18 (44.4)0.0020.74 ± 0.290.003
        III-IV28/33 (84.8)1.04 ± 0.20
    Lymph node metastasis
        No22/32 (68.8)0.7080.89 ± 0.300.564
        Yes14/19 (73.7)0.97 ± 0.22
  • Table 3.

    Relationship between the VEGF mRNA expression and clinicopathologic features in ovarian carcinoma

    VEGF (+)VEGF expression
    Characteristicsn (%)Px ± sP
    Age, years
        ≥ 5124/24 (100)1.0000.82 ± 0.250.121
        < 5127/27 (100)0.71 ± 0.27
    Histological type
        Serous carcinoma39/39 (100)1.0000.77 ± 0.250.446
        Others12/12 (100)0.86 ± 0.32
    Differentiation
        Moderately/Well differentiated11/11 (100)1.0000.77 ± 0.340.762
        Poor differentiated40/40 (100)0.80 ± 0.24
    Clinical stage
        I-II18/18 (100)1.0000.60 ± 0.210.000
        III-IV33/33 (100)0.94 ± 0.22
    Lymph node metastasis
        No32/32 (100)1.0000.74 ± 0.270.031
        Yes19/19 (100)1.00 ± 0.15
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords